These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 22464800)

  • 1. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.
    Harris WJ; Huang X; Lynch JT; Spencer GJ; Hitchin JR; Li Y; Ciceri F; Blaser JG; Greystoke BF; Jordan AM; Miller CJ; Ogilvie DJ; Somervaille TC
    Cancer Cell; 2012 Apr; 21(4):473-87. PubMed ID: 22464800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
    Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
    J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancers of Polycomb EPC1 and EPC2 sustain the oncogenic potential of MLL leukemia stem cells.
    Huang X; Spencer GJ; Lynch JT; Ciceri F; Somerville TD; Somervaille TC
    Leukemia; 2014 May; 28(5):1081-91. PubMed ID: 24166297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Learning from mouse models of MLL fusion gene-driven acute leukemia.
    Schwaller J
    Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
    Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
    Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
    Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?
    Somervaille TC; Cleary ML
    Int J Hematol; 2010 Jun; 91(5):735-41. PubMed ID: 20454944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.
    Wei J; Wunderlich M; Fox C; Alvarez S; Cigudosa JC; Wilhelm JS; Zheng Y; Cancelas JA; Gu Y; Jansen M; Dimartino JF; Mulloy JC
    Cancer Cell; 2008 Jun; 13(6):483-95. PubMed ID: 18538732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. shRNA screening identifies JMJD1C as being required for leukemia maintenance.
    Sroczynska P; Cruickshank VA; Bukowski JP; Miyagi S; Bagger FO; Walfridsson J; Schuster MB; Porse B; Helin K
    Blood; 2014 Mar; 123(12):1870-82. PubMed ID: 24501218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
    Deb G; Wingelhofer B; Amaral FMR; Maiques-Diaz A; Chadwick JA; Spencer GJ; Williams EL; Leong HS; Maes T; Somervaille TCP
    Leukemia; 2020 May; 34(5):1266-1277. PubMed ID: 31780813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioflavonoids promote stable translocations between MLL-AF9 breakpoint cluster regions independent of normal chromosomal context: Model system to screen environmental risks.
    Bariar B; Vestal CG; Deem B; Goodenow D; Ughetta M; Engledove RW; Sahyouni M; Richardson C
    Environ Mol Mutagen; 2019 Mar; 60(2):154-167. PubMed ID: 30387535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six1 regulates leukemia stem cell maintenance in acute myeloid leukemia.
    Chu Y; Chen Y; Li M; Shi D; Wang B; Lian Y; Cheng X; Wang X; Xu M; Cheng T; Shi J; Yuan W
    Cancer Sci; 2019 Jul; 110(7):2200-2210. PubMed ID: 31050834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
    Lillico R; Lawrence CK; Lakowski TM
    J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model.
    Bergerson RJ; Collier LS; Sarver AL; Been RA; Lugthart S; Diers MD; Zuber J; Rappaport AR; Nixon MJ; Silverstein KA; Fan D; Lamblin AF; Wolff L; Kersey JH; Delwel R; Lowe SW; O'Sullivan MG; Kogan SC; Adams DJ; Largaespada DA
    Blood; 2012 May; 119(19):4512-23. PubMed ID: 22427200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
    Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
    Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
    Osaki H; Walf-Vorderwülbecke V; Mangolini M; Zhao L; Horton SJ; Morrone G; Schuringa JJ; de Boer J; Williams O
    Leukemia; 2013 Jul; 27(7):1461-8. PubMed ID: 23403462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape.
    Chiarella E; Aloisio A; Scicchitano S; Todoerti K; Cosentino EG; Lico D; Neri A; Amodio N; Bond HM; Mesuraca M
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells.
    Chen W; Kumar AR; Hudson WA; Li Q; Wu B; Staggs RA; Lund EA; Sam TN; Kersey JH
    Cancer Cell; 2008 May; 13(5):432-40. PubMed ID: 18455126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted down-regulation of MLL-AF9 with antisense oligodeoxyribonucleotide reduces the expression of the HOXA7 and -A10 genes and induces apoptosis in a human leukemia cell line, THP-1.
    Kawagoe H; Kawagoe R; Sano K
    Leukemia; 2001 Nov; 15(11):1743-9. PubMed ID: 11681416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.